Lowell I. Dashefsky has a broad-based transactional practice with extensive experience in structuring and negotiating mergers, acquisitions, private equity investments, divestments, joint ventures, strategic alliances, venture capital financings, and license and collaboration arrangements. He also has experience in public and private securities offerings, and regularly advises companies of various sizes on day-to-day general corporate and other transactional matters.
Mr. Dashefsky represents a variety of multi-national corporations and private companies in various industries, most notably, the private equity and life science/healthcare industries.
- Pfizer Inc. in various acquisitions, investments, and dispositions, including its acquisition of Bamboo Therapeutics Inc. (a biotechnology company focused on developing gene therapies for the treatment of patients with certain rare diseases), InnoPharma, Inc. (a sterile product development company), and NextWave Pharmaceuticals (a specialty pharmaceutical company focused on the development of products for the treatment of attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders), as well as its venture capital investments in several early stage biopharmaceutical companies focused on designing and developing novel therapeutics.
- American Securities in various acquisitions, investments, and dispositions, including its acquisition of Learning Care Group (US) Inc. (a provider of early education and child care services), Frontier Spinning Mills Holding Corp. (a leading producer of cotton yarn for the knitting and weaving industries), and Global Tel*Link Corporation (a leading provider of telecommunications services to correctional facilities in the US), as well as its sale of NEP Broadcasting (a leading provider of outsourced teleproduction services for live sports and entertainment events) and Weasler Engineering Inc. (an agricultural, lawn and turf, and industrial machine drivetrain components maker).
- ACI Capital in a number of transactions, including the sale of Healthy Directions, a US market leader in premium doctor-branded vitamins, minerals and supplements, as well as other health products sold directly to consumers.
- Novartis in the sale of global rights to manufacture, market, and commercialize Elidel® (pimecrolimus) Cream 1% for an upfront payment of US$420 million.
- Arlington Capital Partners in a number of investments, including in Compusearch Systems, Inc., a developer of enterprise software for government agencies.
- J.W. Childs in a number of transactions, including its acquisition and sale of Advantage Sales & Marketing Inc., and its acquisition and sale of EmployBridge Holding Company Inc.
- JD, Brooklyn Law School, 1997
- BS, Union College, 1993, cum laude
- New York